Apixaban may be the preferred DOAC when GI bleeding is a con
There are significant differences in risk of gastrointestinal bleeding across direct oral anticoagulant (DOAC) agents, a new study shows.

Apixaban has the most favorable GI safety profile and rivaroxaban the least favorable, according to the population-based study.

The study also found that GI bleeding events among patient taking DOACs increased with age, with the risk greatest in adults aged 75 and older.

DOACs, including dabigatran, rivaroxaban, apixaban and edoxaban, have been shown to be at least as effective as warfarin for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF)....